Jim Cramer Gives Green Light To This Health Care Stock
Cramer warns against Apple Hospitality if rates hit 6%, prefers Vylor over Corteva, backs Jazz, and notes SpaceX may bid for EchoStar.
Stocks · News reference
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-10-09 AccNo: 0001628280-26-065497 Size: 145 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286
Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $281 to $286.